Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00030108
Other study ID # 020031
Secondary ID 02-C-0031NCI-542
Status Completed
Phase Phase 1
First received January 30, 2002
Last updated March 14, 2012
Start date November 2001
Est. completion date April 2010

Study information

Verified date March 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young patients with relapsed or refractory solid tumors or leukemia.


Description:

OBJECTIVES:

Primary

- Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ixabepilone in young patients with refractory solid tumors (closed to accrual as of 10/4/2007) or relapsed or refractory leukemia.

- Determine the toxicity spectrum of this drug in these patients.

- Determine the plasma pharmacokinetics of this drug in these patients.

- Determine the pharmacodynamics of this drug in these patients.

- Assess the nerve growth factor levels, before and after the initiation of this drug, as a potential surrogate marker for the development of peripheral neuropathy in these patients.

Secondary

- Determine the response of patients treated with this drug.

- Compare the tolerability, toxicity profile, MTD, DLT, pharmacokinetics, and pharmacodynamics of this drug in young patients treated on this study vs adults with solid tumors (closed to accrual as of 10/4/2007) treated on the ongoing Medicine Branch, NCI, phase I study.

- Assess the safety and tolerability of ixabepilone at the solid tumor MTD (expanded leukemia cohort).

- Evaluate the plasma pharmacokinetics of in young patients with refractory or relapsed leukemia.

- Evaluate the extent of tubulin polymerization in leukemic blasts at baseline after treatment with ixabepilone ex-vivo.

- Compare the effects of tubulin polymerization in leukemic blasts with ixabepilone versus paclitaxel ex-vivo with an without the presence of a potent P-glycoprotein inhibitor.

- Evaluate the activity known drug transporters in drug-resistant leukemias in leukemic blasts.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive ixabepilone IV over 1 hour on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience dose-limiting toxicity. Intrapatient dose escalation to one dose level above the enrollment dose level is allowed in patients who have stable or responding disease or are experiencing other benefits from therapy (e.g., decrease in tumor-related pain symptoms) and who have no grade 2 or greater non-hematologic toxicity and no grade 3 or greater hematologic toxicity. Additional patients are treated at the MTD. Patients treated at the MTD may not undergo intrapatient dose escalation.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 1-2 years.


Other known NCT identifiers
  • NCT00025961

Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- Meets 1 of the following criteria:

- Histologically confirmed solid tumor (closed to accrual as of 10/4/2007) that relapsed after or failed to respond to front-line curative therapy and for which no other potentially curative treatment options exist

- Curative therapy may include surgery, radiotherapy, chemotherapy, or any combination of these modalities

- Eligible tumor types include, but are not limited to, the following:

- Rhabdomyosarcoma

- Other soft tissue sarcomas

- Ewing's sarcoma family of tumors

- Osteosarcoma

- Neuroblastoma

- Wilms' tumor

- Hepatic tumors

- Germ cell tumors

- Primary brain tumors

- Histologic confirmation may be waived for brain stem or optic glioma

- Diagnosis of relapsed or refractory leukemia

- Patients with refractory or second or greater relapsed leukemia must have > 25% blasts in the bone marrow (M3 bone marrow) with or without active extramedullary disease (except for leptomeningeal disease)

- Relapsed after or failed to respond to frontline curative therapy and no other potentially curative therapy (e.g., radiotherapy, chemotherapy, or any combination of these modalities) exists

- Patients with acute promyelocytic leukemia must be refractory to treatment with retinoic acid and arsenic trioxide

- Patients with Philadelphia chromosome positive chronic myelogenous leukemia must be refractory to imatinib

- No active CNS leukemia (CNS3)

PATIENT CHARACTERISTICS:

Age:

- 2 to 18 (solid tumor patients [closed to accrual as of 10/4/2007])

- 1 to 21 (leukemia patients)

Performance status:

- For patients age 11 to 21:

- Karnofsky 50-100%

- For patients age 1 to 10:

- Lansky 50-100%

Life expectancy:

- Not specified

Hematopoietic:

- Platelet count at least 100,000/mm^3 (20,000/mm^3 for leukemia patients)

- Hemoglobin = 8.0 g/dL

Hepatic:

- Bilirubin less than 1.5 times upper limit of normal (ULN)

- SGOT and SGPT less than 2.5 times ULN

- No hepatic dysfunction that would preclude study

Renal:

- Creatinine normal for age OR

- Creatinine clearance at least 60 mL/min

- No renal dysfunction that would preclude study

Other:

- No known severe prior hypersensitivity reaction to agents containing Cremophor EL

- No clinically significant unrelated systemic illness (e.g., serious infections or other organ dysfunction) that would preclude study

- No grade 2 or greater preexisting sensory neuropathy

- More than 2 month since prior and no concurrent evidence of graft vs host disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Recovered from all therapy-related acute toxic effects (leukemia patients only)

- Prior epoetin alfa allowed

- At least 3 days since other prior colony-stimulating factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-11 (IL-11))

- At least 6 months since prior bone marrow transplantation

- At least 2 months since prior stem cell transplantation or rescue (leukemia patients)

- At least 7 days since prior therapy with a biological agent and hematopoietic growth factor with the exception of erythropoietin

- More than 3 weeks since prior monoclonal antibody therapy (leukemia patients only)

- No concurrent GM-CSF or IL-11

- No concurrent immunotherapy

Chemotherapy:

- See Disease Characteristics

- Recovered from all therapy-related acute toxic effects (leukemia patients only)

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

- No other concurrent anticancer chemotherapy

Endocrine therapy:

- Concurrent corticosteroids allowed for the control of symptoms related to tumor-associated edema in patients with brain tumors

- Patients with brain tumors must be on a stable or tapering dose of corticosteroids for 7 days before baseline scan is performed for the purpose of assessing response to study therapy

- Must be on a stable or tapering dose of corticosteroids for 7 days prior to study entry (leukemia patients only)

Radiotherapy:

- See Disease Characteristics

- Recovered from all therapy-related acute toxic effects (leukemia patients only)

- At least 4 weeks since prior radiotherapy

- More than 2 weeks since prior local palliative radiotherapy (leukemia patients only)

- More than 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to =50% of the pelvis (leukemia patients only)

- More than 6 weeks since prior other substantial bone marrow radiotherapy (leukemia patients only)

- No prior extensive radiotherapy (e.g., craniospinal irradiation, total body irradiation, or radiotherapy to more than half of the pelvis)

- No concurrent anticancer radiotherapy

Surgery:

- See Disease Characteristics

Other:

- Recovered from prior therapy

- At least 30 days since any prior investigational anticancer therapy

- At least 1 week since prior known inhibitors of CYP3A4, including any of the following:

- Antibiotics (i.e., clarithromycin, erythromycin, or troleandomycin)

- Anti-HIV agents (i.e, delaviridine, nelfinavir, amprenavir, ritonavir, idinavir, saquinavir, or lopinavir)

- Anti-fungals (i.e., itraconazole, ketoconazole, fluconazole [doses > 3mg/kg/day], or voriconazole)

- Anti-depressants (i.e., nefaxodone or fluovoxamine)

- Calcium channel blockers (i.e., verapamil or diltiazem)

- Anti-emetics (i.e., aprepitant [Emend®])

- Miscellaneous agents (i.e., amiodarone)

- Grapefruit juice

- No other concurrent investigational agents

- No concurrent St. John's Wort

- No concurrent known inhibitors of CYP3A4, including grapefruit juice

- Concurrent other agents inducing CYP3A4 allowed

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
ixabepilone


Locations

Country Name City State
United States Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda Maryland
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose and dose-limiting toxicity of ixabepilone Yes
Primary Toxicity spectrum Yes
Primary Plasma pharmacokinetics No
Primary Pharmacodynamics No
Primary Nerve growth factor levels before and after drug administration No
Secondary Objective tumor response No
Secondary Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1 No
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2